NATCOPHARM - Trend Reversal Strenght PatternNATCOPHARM
Looks Good for SWING TRADE
Shows trend reversal strenght pattern.
Trading near 200 daily ema.
Volume building..
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
105.25 INR
18.85 B INR
44.30 B INR
86.73 M
About NATCO PHARMA LTD.
Sector
Industry
CEO
Rajeev Nannapaneni
Website
Headquarters
Hyderabad
Founded
1981
ISIN
INE987B01026
FIGI
BBG000F4LSP2
NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. It operates through the following segments: Domestic Formulations, International Formulations, and Active Pharmaceutical Ingredients. The Domestic Formulations segment operates in the divisions of oncology, pharma specialties and CnD. The International Formulations segment exports its FDF products from India to several international geographies either through its local partners or directly through its subsidiaries such as in Canada and Brazil. The Active Pharmaceutical Ingredients segment is strategically important as it develops APIs for the captive consumption of many of NATCO's critical FDF products in addition to supplying to direct customers. The company was founded by Venkaiah Chowdary Nannapaneni in 1981 and is headquartered in Hyderabad, India.
Related stocks
NATCOPHARM - Weekly AnalysisIn the Weekly Chart of NATCOPHARM ,
we can see that; it is at decision making point.
Possible momentums are shown in chart.
Natco Pharma - Enough CorrectionCMP 875 on 22.05.25
The stock price dropped 50% between September 2024 and March 2025. In recent days, it has been consolidating near the 800 levels, which is acting as a support zone, as shown on the chart.
MACD shows a likely crossover, too.
If it gives an upside move, further targets may be 1080/
Stock Analysis: NATCO Pharma Limited (NATCO)Introduction:
NATCO Pharma Limited (NATCO) is a vertically integrated, research and development-focused pharmaceutical company that develops, manufactures, and markets complex products for niche therapeutic areas. NATCO is actively involved in three business segments viz. finished dosage formulati
Natco Pharma, building a reversal thesisNatco Pharma is the weakest in the mid cap space down more than 55% from its recent ATH. Now that POTUS has given a 90 day pause on imposition of reciprocal tariffs and further Pharma continuing to be an exempt tariff import item some optimism can return to this counter.
I would start my bullish t
NATCOPHARM - Beaten Down Stock, Available attractively for inves NATCOPHARM - Beaten Down Stock, Available attractively for investment only
Fundamental Outlook
Almost debt free D/E ratio is 0.3, High ICR
PE of 7.95, Very attractive
PEG of 0.47, very attractive
ROE = 25.92%
ROCE = 30.1% , ROCE 5yrs = 15.85 %
Sales growth = 11.71%, Sales Growth 5 yrs 13.81%
add at currevt levles and keep adding till 800fundamentally beautiful stock to be in your portfolio. great levels to do sip in this stock . bulk sip at these levels 5 year horizon for 3000 levels
SWING OBSERVATION - NATCO PHARMA
Script opened huge gap down yesterday around major support levels 980 and down move continues - now below 0.2 fib which may lead to testing of next swing or fib bottom 800 till 720
Natco Pharma - A bleeding story with no healing sign.Natco pharma dropped 20% intraday post reporting quarterly no.s
What are the reasons? Should one pick this stock now?
Let's analyse in this video.
Natco : Weaker forecast hitting it hard technically- Q3 results were out Yesterday, and were week with significant weaker forecast !
- Technically, Natco Pharma should test it’s quarterly + monthly demand area of 800 - 740, and go in time correction thereafter with minor bounce
- On any bounce, 1200 - 1300 is going to act as very strong resistance i
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of NATCOPHARM is 984.00 INR — it has decreased by −1.74% in the past 24 hours. Watch NATCO PHARMA LTD. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BSE exchange NATCO PHARMA LTD. stocks are traded under the ticker NATCOPHARM.
NATCOPHARM stock has risen by 7.86% compared to the previous week, the month change is a 15.15% rise, over the last year NATCO PHARMA LTD. has showed a −17.94% decrease.
We've gathered analysts' opinions on NATCO PHARMA LTD. future price: according to them, NATCOPHARM price has a max estimate of 1,460.00 INR and a min estimate of 772.00 INR. Watch NATCOPHARM chart and read a more detailed NATCO PHARMA LTD. stock forecast: see what analysts think of NATCO PHARMA LTD. and suggest that you do with its stocks.
NATCOPHARM reached its all-time high on Sep 12, 2024 with the price of 1,638.35 INR, and its all-time low was 7.60 INR and was reached on Oct 27, 2008. View more price dynamics on NATCOPHARM chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
NATCOPHARM stock is 2.47% volatile and has beta coefficient of 1.14. Track NATCO PHARMA LTD. stock price on the chart and check out the list of the most volatile stocks — is NATCO PHARMA LTD. there?
Today NATCO PHARMA LTD. has the market capitalization of 182.21 B, it has increased by 7.04% over the last week.
Yes, you can track NATCO PHARMA LTD. financials in yearly and quarterly reports right on TradingView.
NATCO PHARMA LTD. is going to release the next earnings report on Aug 7, 2025. Keep track of upcoming events with our Earnings Calendar.
NATCOPHARM earnings for the last quarter are 22.85 INR per share, whereas the estimation was 10.80 INR resulting in a 111.57% surprise. The estimated earnings for the next quarter are 36.90 INR per share. See more details about NATCO PHARMA LTD. earnings.
NATCO PHARMA LTD. revenue for the last quarter amounts to 12.21 B INR, despite the estimated figure of 12.91 B INR. In the next quarter, revenue is expected to reach 14.91 B INR.
NATCOPHARM net income for the last quarter is 4.07 B INR, while the quarter before that showed 1.33 B INR of net income which accounts for 205.71% change. Track more NATCO PHARMA LTD. financial stats to get the full picture.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. NATCO PHARMA LTD. EBITDA is 21.96 B INR, and current EBITDA margin is 49.58%. See more stats in NATCO PHARMA LTD. financial statements.
Like other stocks, NATCOPHARM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade NATCO PHARMA LTD. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So NATCO PHARMA LTD. technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating NATCO PHARMA LTD. stock shows the buy signal. See more of NATCO PHARMA LTD. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.